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ABSTRACT
The pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir were compared in
allogeneic stem cell transplant recipients with stable graft-versus-host disease of the gastrointestinal tract.
Twenty-two evaluable adult patients were randomized to receive a single dose of open-label study drug (900
mg of oral valganciclovir or 5 mg/kg of intravenous ganciclovir). After a washout period of 2 to 7 days, patients
were crossed over to receive the alternate study drug. Ganciclovir and valganciclovir concentrations in plasma
were measured over 24 hours after dosing. Noninferiority of 900 mg of valganciclovir relative to intravenous
ganciclovir was concluded if the lower limit of the 1-sided 95% confidence interval of the ratio of least-square
means of the ganciclovir area under the curve (AUC) for the 2 study drugs was>80%. Valganciclovir was found
to be rapidly absorbed and converted into ganciclovir. The ganciclovir exposure after 900 mg of valganciclovir
noninferior to that of intravenous ganciclovir (AUC0-, 52.1 and 53.8 g·h/mL, respectively; 95% confidence
interval of the ratio of least square means of AUC0-, 82.48%-118.02%). Oral valganciclovir could be a useful
alternative to intravenous ganciclovir in certain stable stem cell transplant patients who require prophylaxis or
preemptive therapy for cytomegalovirus infection.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Cytomegalovirus (CMV) disease can be effec-
ively prevented in allogeneic hematopoietic stem
ell transplant recipients by using ganciclovir. Pre-
entive strategies that use ganciclovir include the
nitiation of preemptive therapy only in patients who
ecome positive for CMV antigen or CMV DNA in
he blood after transplantation and universal prophy-
axis initiated in all patients at the time of engraftment
nd continued until day 100 after transplantation v
B&MT1-4]. Because of the low bioavailability of oral gan-
iclovir capsules, ganciclovir is usually administered
ntravenously through a central venous catheter to
ematopoietic stem cell transplant patients [5]. Al-
hough effective, this route of administration is lim-
ted by inconvenience, cost, and the risk of line-
elated infections.
Valganciclovir is a valine ester prodrug of ganci-
lovir. After oral administration, the vast majority of
alganciclovir is converted rapidly by hydrolysis to
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6anciclovir. In human immunodeﬁciency virus (HIV)–
nfected patients and solid-organ transplant recipients,
he oral bioavailability of valganciclovir is approxi-
ately 60%, or 10-fold higher than the bioavailability
f oral ganciclovir capsules [6,7]. Studies in HIV-
nfected patients and liver transplant recipients have
hown that a 900-mg dose of oral valganciclovir re-
ults in an area under the plasma concentration-time
urve (AUC) for ganciclovir similar to that of intra-
enous ganciclovir 5 mg/kg/d [7,8].
Patients who develop graft-versus-host disease
GVHD) after allogeneic hematopoietic stem cell
ransplantation are especially at risk for CMV disease
nd thus frequently require preemptive or prophylac-
ic ganciclovir therapy. However, GVHD that in-
olves the gastrointestinal tract can be particularly
roublesome, causing severe diarrhea and decreased
bsorption of certain drugs such as cyclosporine [9,10]. If
ral valganciclovir is to become an appropriate alter-
ative to intravenous ganciclovir for allogeneic hema-
opoietic stem cell transplant recipients, then the
harmacokinetic proﬁle of oral valganciclovir in pa-
ients with GVHD that involves the gastrointestinal
ract needs to be established. For this reason, we
ndertook this study to compare the pharmacokinetic
arameters of ganciclovir after oral valganciclovir ver-
us intravenous ganciclovir in stem cell transplant re-
ipients with stable GVHD of the gastrointestinal
ract.
ETHODS
atients
Patients who had received an allogeneic hemato-
oietic stem cell transplant were eligible for the study
f the following criteria were satisﬁed: (1)16 years of
ge, (2) absolute neutrophil count of 1000 cells per
icroliter, (3) calculated creatinine clearance 60
L/min, (4) no active CMV infection or disease, and
5) GVHD of the gastrointestinal tract. The diagnosis
f GVHD was established by standard criteria [11,12].
VHD of the gastrointestinal tract was deﬁned as
iopsy-proven GVHD of the gastrointestinal tract
lus diarrhea (300-1500 mL/d) and/or nausea or bi-
psy-proven GVHD of the liver or skin plus diarrhea
300-1500 mL/d) with no other explanation. Patients
ho had received ganciclovir or acyclovir within 96
ours before the start of the study were excluded.
mmunosuppressive agents were used as clinically in-
icated, but doses of cyclosporine and tacrolimus were
ept stable during the duration of the study. The study
as approved by the institutional review board at each
ransplant center. Informed consent was obtained
rom each patient before enrollment. v
36tudy Design
Eligible patients were randomized to receive a
ingle dose of open-label study drug (900 mg of oral
alganciclovir or intravenous ganciclovir at a dosage of
mg/kg of actual body weight). After a washout
eriod of 2 to 7 days, patients were crossed over to
eceive the alternate study drug. Each dose of study
rug was administered in the morning after an over-
ight fast and then a standardized breakfast (cereal
ith milk, toast with butter and jam, juice, and coffee
r tea). All patients also received a light lunch and
vening meal.
aboratory Studies and Clinical Assessments
Complete blood counts, serum creatinine and blood
rea determinations, urinalyses, and liver function stud-
es (total serum bilirubin, serum glutamic oxaloacetic
ransaminase, serum glutamic pyruvic transaminase, and
lkaline phosphatase) were performed before and after
ach treatment period. Creatinine clearance was calcu-
ated before each dose of study drug by using the Cock-
roft-Gault equation. A serum pregnancy test for female
atients and a test for CMV antigen or DNA in the
lood were performed before the study started.
Blood for plasma levels of ganciclovir and valgan-
iclovir was drawn before administration of the study
rug and then at 5 minutes, 15 minutes, 30 minutes,
5 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3
ours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours,
nd 24 hours after study drug administration. When a
atient had received intravenous ganciclovir, blood
as drawn from the arm opposite the injection site of
ntravenous ganciclovir. Blood samples were centri-
uged immediately. Plasma was extracted and stored at
70°C until analysis. Plasma levels of ganciclovir and
alganciclovir were determined by a speciﬁc high-
ressure liquid chromatography column-switching
ethod and mass spectrometry [13,14].
A complete medical history, physical examination,
nd list of medications were recorded before the
tudy. Patients were assessed for adverse events after
ach dose of study medication.
harmacokinetic Parameters
Pharmacokinetic parameters were derived by non-
ompartmental methods by using the WinNonlin Pro-
essional Version 4.1 software package, NCA model 202
Pharsight Corporation, Mountain View, CA). Sam-
les below the limit of quantiﬁcation at the beginning
r end of the proﬁles were considered to have a value
f 0 g/mL, whereas values below the limit of quan-
iﬁcation that occurred during the proﬁle were as-
umed to be missing. The primary pharmacokinetic
arameter was the plasma ganciclovir AUC from time
to inﬁnity (AUC0-) after either 900 mg of oralalganciclovir or 5 mg/kg of intravenous ganciclovir
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Bdministered over 1 hour. The AUC0- was calculated
y using the linear-trapezoidal method up to the max-
mum observed plasma ganciclovir concentration
aken directly from the concentration-time data for each
atient (Cmax) and by using the log-linear-trapezoidal
ethod after Cmax (AUC0-  AUC0-t  Clast/z). Clast
s the last measurable plasma concentration, and z is the
rst-order rate constant associated with the terminal
log-linear) portion of the plasma concentration curve.
ther pharmacokinetic parameters used for comparison
ere AUC0-t (plasma ganciclovir AUC from 0 to t hours
sing the linear trapezoidal method), Cmax, time to Cmax,
z (terminal elimination rate constant), and terminal
limination half-life, calculated as the Ln(2)/z.
tatistics
On the basis of a previous pharmacokinetic study
hat compared intravenous or oral ganciclovir with
alganciclovir in liver transplant patients [7], the with-
n-subject coefﬁcient of variation for the AUC0- was
stimated to be 16.9%. A 20% increase in the coefﬁ-
ient of variation was used to account for additional
ariability that may occur in stem cell transplant re-
ipients. When this estimate of variability is used, a
otal sample size of 20 evaluable patients (10 per se-
uence group) is needed to establish the noninferior-
ty of the ganciclovir AUC0- after oral valganciclovir
ersus intravenous ganciclovir on the basis of a  of
0% and a 1-sided 	 of .05 with 80% power. To
ccount for possible dropouts, a total of 24 patients
ere enrolled in the study.
The pharmacokinetic analysis was based on data
nly from patients who completed both treatment
eriods of the study. An analysis of variance model
or the 2-way crossover design was used to assess the
atio of the means of AUC0- for ganciclovir after oral
alganciclovir versus intravenous ganciclovir. Nonin-
eriority was concluded if the lower limit of the
-sided 95% conﬁdence interval of the ratio of least
quare means of the ganciclovir AUC0- after valgan-
iclovir versus intravenous ganciclovir was 80%.
ther pharmacokinetic parameters were summarized
y treatment group by using descriptive statistics.
ESULTS
A total of 24 patients were enrolled in the study.
welve patients were randomized to each treatment
equence (valganciclovir followed by intravenous gan-
iclovir or intravenous ganciclovir followed by valgan-
iclovir). Two patients assigned to the sequence of
ntravenous ganciclovir followed by valganciclovir
ere excluded from analysis. One patient withdrew
rom the study before receiving any study drug, and a
econd patient withdrew after receiving only intrave-
ous ganciclovir. m
B&MTThe demographics of the 22 evaluable patients are
ummarized in Table 1. All patients were adults with
mean weight of 76 kg. Eight patients had acute
VHD, and 14 patients had chronic GVHD. Nine-
een patients had GVHD of the gastrointestinal tract
ocumented by a biopsy. Two patients with chronic
VHD had diarrhea (which had no other explanation)
nd biopsy-proven GVHD of the liver. Their diarrhea
tabilized on increased immunosuppressive therapy.
ne patient with clinical evidence of acute GVHD of
he liver and gastrointestinal tract responded to cor-
icosteroids but had an inconclusive gastrointestinal
iopsy. All patients were taking immunosuppressive
rugs at the time of study. Twenty of the 22 patients
ere receiving corticosteroids in combination with
acrolimus, cyclosporine, or sirolimus. The median
ime after transplantation for entering the study was
27 days. Nine patients were studied 
6 months after
ransplantation, whereas 13 patients were studied 6
onths after transplantation. The mean interval be-
ween administration of the 2 study drugs was 5.2
ays.
Mean plasma ganciclovir concentrations over time
re shown in Figure 1. The mean ganciclovir concen-
ration in plasma after intravenous ganciclovir reached
maximum of approximately 13 g/mL in approxi-
able 1. Patient Demographics
Variable Data
o. patients 22
ean age, y (range) 45 (23-63)
ex (n)
Male 16
Female 6
ean weight, kg (range) 76 (52-107)
nderlying disease (n)
Lymphoma 7
Acute leukemia 5
Chronic leukemia 5
Multiple myeloma 2
Aplastic anemia 2
Myelodysplastic syndrome 1
VHD (n)
Chronic 14
Acute (grade II or III) 8
iopsy-proven GVHD (n)
Gastrointestinal 19
Liver 2
None 1
mmunosuppressive drugs (n)
Tacrolimus, corticosteroids 9
Tacrolimus, corticosteroids, mycophenolate 1
Tacrolimus 2
Cyclosporine, corticosteroids 6
Cyclosporine, corticosteroids, mycophenolate 1
Sirolimus, corticosteroids 3
edian time (range) after transplantation for
entry onto study (d) 227 (61-988)
ean creatinine clearance, mL/min (range) 92 (45-182)ately 1 hour, which was approximately 2.5 hours
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6arlier than the mean maximum ganciclovir concen-
ration of approximately 6.0 g/mL after oral valgan-
iclovir. After reaching maximum concentrations, the
ean plasma ganciclovir concentrations after both
ntravenous ganciclovir and oral valganciclovir de-
lined and decreased to 
1.0 g/mL at 16 hours after
dministration. In contrast, the mean peak concentra-
ion of valganciclovir was only 0.22 g/mL at 2.5
ours after dosing and declined rapidly, decreasing
elow the limit of quantiﬁcation within 6 hours of
osing (Figure 2).
Mean ganciclovir pharmacokinetic parameters with
oefﬁcients of variation are summarized in Table 2. Be-
ause there were no signiﬁcant statistical differences in
he pharmacokinetic parameters by treatment se-
uence, results are presented by treatment (oral val-
anciclovir versus intravenous ganciclovir). The mean
anciclovir AUC0- and AUC0-t values associated with
ral valganciclovir and intravenous ganciclovir were
imilar. Because the lower limit of the 1-sided 95%
onﬁdence interval (82.48%-118.02%) of the ratio of
east square means of the AUC0- for ganciclovir after
alganciclovir versus intravenous ganciclovir was
80%, the noninferiority of valganciclovir compared
ith intravenous ganciclovir was established. Simi-
igure 1. Mean plasma ganciclovir concentration over time after
osing with 900 mg of oral valganciclovir or 5 mg/kg of intravenous
anciclovir.
igure 2. Mean plasma valganciclovir concentration over time after
Aosing with 900 mg of oral valganciclovir.
38arly, the lower limit of the 1-sided 95% conﬁdence
nterval (81.58%-116.77%) of the ratio of least square
eans of the AUC0-t for ganciclovir after valganciclo-
ir versus intravenous ganciclovir was 80%. The
ean Cmax value (6.7 g/mL) after oral administra-
ion of valganciclovir was lower than the mean Cmax
alue (13.3 g/mL) after intravenous administration
f ganciclovir. The mean time to Cmax for ganciclovir
as also longer (3.5 versus 0.9 hours) after oral val-
anciclovir. The mean terminal elimination ganciclo-
ir rate constant, or z (0.1 1/h versus 0.1 1/h), and the
ean terminal elimination ganciclovir half-life (5.1
ersus 5.2 hours) were similar after valganciclovir and
ntravenous ganciclovir. There were no signiﬁcant dif-
erences in the ganciclovir pharmacokinetic parame-
ers after valganciclovir versus intravenous ganciclovir
hen patients with acute GVHD were compared with
atients with chronic GVHD. Similarly, no associa-
ion could be made between pharmacokinetic param-
ters and the amount of diarrhea.
Adverse events related to study drug administra-
ion occurred in only 1 (4.3%) of the 23 patients who
eceived a study drug. One patient experienced dizzi-
ess and a visual ﬁeld defect during administration of
ntravenous ganciclovir. Both adverse events resolved
ithout sequelae. There were no laboratory abnor-
alities related to the study drugs.
ISCUSSION
Although higher and earlier maximum plasma
anciclovir concentrations were achieved after intra-
enous ganciclovir compared with oral valganciclovir,
e found that the mean AUC0- and AUC0-t values
or ganciclovir after these 2 drugs were similar in
atients with stable GVHD of the gastrointestinal
ract. These results are consistent with those of a
harmacokinetic study in liver transplant patients
hich compared oral valganciclovir with intravenous
anciclovir [7]. The mean values for the AUC0- and
able 2. Mean Ganciclovir Pharmacokinetic Parameters after Dosing
ith Oral Valganciclovir or Intravenous Ganciclovir
Parameter
900 mg of Oral
Valganciclovir
(n  22)
5 mg/kg of Intravenous
Ganciclovir
(n  22)
UC0- (g·h/mL) 52.1 (41) 53.8 (40)
UC0-t (g·h/mL) 49.0 (37) 51.3 (37)
max (g/mL) 6.7 (27) 13.3 (30)
max (h) 3.5 (26) 0.9 (14)
z (1/h) 0.1 (38) 0.1 (28)
1/2 (h) 5.1 (28) 5.2 (29)
alues in parentheses are coefﬁcients of variation (%).
max indicates time to Cmax; z, terminal elimination rate constant;
t1/2, terminal elimination half-life.UC0-t of ganciclovir after dosing with 900 mg of oral
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Balganciclovir were 52.1 and 49.0 g·h/mL, respec-
ively, in our study compared with 43.9 and 41.7
g·h/mL, respectively, in liver transplant recipients
ho received 900 mg of valganciclovir. These values
n stem cell and liver transplant recipients are higher
han the mean AUC0-t value of 24.8 g·h/mL ob-
erved in HIV-infected patients after 875 mg of oral
alganciclovir [8]. The terminal elimination ganciclo-
ir half-life after oral valganciclovir is also longer in
oth stem cell (5.1 hours) and liver (5.1 hours) trans-
lant recipients compared with HIV-infected patients
4.08 hours) [7,8]. The use of immunosuppressive
gents and other drugs with potential nephrotoxicity
n transplant patients may decrease the renal clearance
f ganciclovir.
The amount and extent of exposure to valganci-
lovir in this study were low. The mean peak concen-
ration of valganciclovir was 0.22 g/mL at 2.5 hours
fter dosing. Valganciclovir levels became undetect-
ble 6 hours after dosing. In liver transplant recipients
nd HIV-infected patients, similar low Cmax values for
alganciclovir (0.172 and 0.264 g/mL, respectively)
ere noted after 900- or 875-mg doses of oral valgan-
iclovir [7,8]. These results are consistent with the
apid and almost complete metabolism of valganciclo-
ir to ganciclovir [6].
In a previous pharmacokinetic study in stem cell
ransplant recipients, oral ganciclovir was evaluated in
4 patients without gastrointestinal GVHD and in 7
atients with gastrointestinal GVHD [5]. The abso-
ute bioavailability of oral ganciclovir was low but
imilar in patients with or without gastrointestinal
VHD (7.2% versus 6.9%, respectively). The mean
UC0- values for ganciclovir were also comparable
n patients with or without gastrointestinal GVHD
13.5 and 10.2 g·h/mL, respectively). However,
hese AUC0- values are considerably lower than the
ean AUC0- value for ganciclovir (52.1 g·h/mL)
fter oral valganciclovir in our study. The lower
UC0- values after oral ganciclovir were associated
ith a 38% incidence of breakthrough CMV viremia
mong patients taking prophylactic oral ganciclovir
1000 mg 3 times per day) from day 35 to day 100 after
ransplantation [5]. Oral valganciclovir also provides
reater systemic exposure to ganciclovir than oral gan-
iclovir in solid-organ transplant recipients [15]. In a
reliminary report of a multiple-dose pharmacoki-
etic study of valganciclovir in allogeneic stem cell
ransplant recipients, exposure to ganciclovir after
reemptive therapy with valganciclovir for CMV vire-
ia was comparable to that with intravenous ganci-
lovir in patients with and without gastrointestinal
VHD [16].
A limitation of this study is that patients were
valuated when their gastrointestinal GVHD and di-
rrhea (300-1500 mL/d) were relatively stable. In ad- g
B&MTition, many patients had chronic GVHD. Patients
ith more severe diarrhea that complicated unstable
cute GVHD were excluded. However, these more ill
atients frequently need hospitalization for treatment
f GVHD and require intravenous therapy not only
ith ganciclovir, but also with other medications. Af-
er their GVHD improves and stabilizes, they may
ecome candidates for oral valganciclovir. Although
atients with chronic GVHD are generally at lower
isk for CMV disease compared with patients with
cute GVHD, late-onset CMV infection and disease
ave been associated with increased mortality [17].
onsequently, both prophylaxis and preemptive ther-
py with oral valganciclovir are being considered in
atients with chronic GVHD, who often no longer
ave an intravenous line.
The single doses of valganciclovir in this study
ere generally well tolerated. However, the complete
afety proﬁle of valganciclovir in stem cell transplant
atients can be determined only in larger studies that
se multiple doses over a longer time. Neutropenia
as been the primary dose-limiting toxicity of intra-
enous ganciclovir in stem cell transplant recipients
1-4]. In controlled trials that evaluated the efﬁcacy
nd safety of oral valganciclovir in HIV-infected pa-
ients and liver transplant recipients, the incidence of
eutropenia associated with valganciclovir was 8.2%
o 14% and was similar to the incidence with intrave-
ous or oral ganciclovir [18,19].
Although the results of this study suggest that oral
alganciclovir could be a useful alternative to intrave-
ous ganciclovir in certain stable stem cell transplant
ecipients who require prophylaxis or preemptive
herapy for CMV, this study was not designed to
valuate efﬁcacy. Currently, valganciclovir is approved
or treatment of CMV retinitis in patients with ac-
uired immunodeﬁciency syndrome and for preven-
ion of CMV disease in CMV-seronegative kidney,
eart, and kidney-pancreas transplant patients with
MV-seropositive donors [18,19]. In uncontrolled stud-
es, preemptive therapy with valganciclovir appeared to
revent CMV disease in both liver and stem cell trans-
lant patients [20,21]. Additional randomized studies are
eeded to fully deﬁne the efﬁcacy and safety of valgan-
iclovir as preemptive therapy or as long-term prophy-
axis of CMV disease in stem cell transplant recipients.
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